General Information of Drug Combination (ID: DCHLWSL)

Drug Combination Name
Amonafide Vincristine
Indication
Disease Entry Status REF
Cutaneous melanoma Investigative [1]
Component Drugs Amonafide   DMAH59S Vincristine   DMINOX3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SK-MEL-5
Zero Interaction Potency (ZIP) Score: 3.02
Bliss Independence Score: 2.91
Loewe Additivity Score: 2.46
LHighest Single Agent (HSA) Score: 4.67

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of Vincristine
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [3]
Adult kidney Wilms tumor N.A. Approved [4]
Beckwith-Wiedemann syndrome N.A. Approved [4]
Burkitt lymphoma N.A. Approved [4]
Central nervous system neoplasm N.A. Approved [4]
Childhood acute lymphoblastic leukemia N.A. Approved [4]
Childhood kidney Wilms tumor N.A. Approved [4]
Hamartoma N.A. Approved [4]
Kidney neoplasm N.A. Approved [4]
Leukemia N.A. Approved [4]
MALT lymphoma N.A. Approved [4]
Nodal marginal zone lymphoma 2A85.0 Approved [4]
Plasma cell myeloma 2A83.1 Approved [4]
Primitive neuroectodermal tumor N.A. Approved [4]
Splenic marginal zone lymphoma N.A. Approved [4]
Testicular lymphoma N.A. Approved [4]
Wilms tumor N.A. Approved [4]
Classic Hodgkin lymphoma N.A. Investigative [4]
Follicular lymphoma 2A80 Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Vincristine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Vincristine Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [6]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Vincristine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCOVWI2 DU-145 Investigative [1]
Adenocarcinoma DCFMQZ0 A549 Investigative [1]
Adenocarcinoma DCVFX46 SW-620 Investigative [1]
Adenocarcinoma DCZ1STM HCT116 Investigative [1]
Adenocarcinoma DCGARNE HCT-15 Investigative [1]
Adult T acute lymphoblastic leukemia DCDPHB1 MOLT-4 Investigative [1]
Astrocytoma DCK4QWA U251 Investigative [1]
Clear cell renal cell carcinoma DC2HR4A 786-0 Investigative [1]
Clear cell renal cell carcinoma DCS8I24 A498 Investigative [1]
Glioma DC4K52B SF-268 Investigative [1]
Large cell lung carcinoma DCOE57D NCI-H460 Investigative [1]
Lung adenocarcinoma DCC6WVF HOP-62 Investigative [1]
Non-small cell lung carcinoma DCMBB49 HOP-92 Investigative [1]
Papillary renal cell carcinoma DCY319L ACHN Investigative [1]
Invasive ductal carcinoma DC7EHVI BT-549 Investigative [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
4 Vincristine FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
9 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
10 Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
11 Drug Interactions Flockhart Table
12 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.